Comparative Pharmacology
Head-to-head clinical analysis: FOSFOMYCIN TROMETHAMINE versus MYCIFRADIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FOSFOMYCIN TROMETHAMINE versus MYCIFRADIN.
FOSFOMYCIN TROMETHAMINE vs MYCIFRADIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fosfomycin inhibits bacterial cell wall synthesis by inactivating the enzyme UDP-N-acetylglucosamine enolpyruvyl transferase (MurA), which catalyzes the first step of peptidoglycan biosynthesis.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, inhibiting bacterial protein synthesis by causing misreading of mRNA and incorporation of incorrect amino acids into the growing peptide chain.
3 g orally once as a single dose for uncomplicated urinary tract infection.
1-2 g orally every 6 hours for 7-14 days. Or 500 mg intramuscularly every 12 hours.
None Documented
None Documented
Terminal elimination half-life is 5.7 hours (range 3-8 hours) in patients with normal renal function; approximately 50 hours in end-stage renal disease (CrCl <10 mL/min).
Terminal elimination half-life is 9–12 hours in patients with normal renal function; may extend to >20 hours in impaired renal function, necessitating dose adjustment.
Primarily excreted unchanged in urine via glomerular filtration (approximately 90% of absorbed dose within 24-48 hours); small amount (approximately 10%) excreted in feces via biliary elimination.
Primarily renal excretion of unchanged drug via glomerular filtration; >90% of absorbed dose excreted unchanged in urine within 24 hours. Minor biliary excretion (<1%) with fecal elimination accounting for <1%.
Category A/B
Category C
Antibiotic
Antibiotic